Announcement
In January 2018 over 100 people from across the ECMC network came to Manchester to attend the sixth annual two day Junior Investigator Network Group (JING): Training the Next Generation event. This two day residential is aimed at junior investigators wishing to pursue and develop in the area of early phase trials and translational research within the ECMCs. Attendees included trainees, faculty, speakers and patient and public involvement representatives.
A collaborative workshop relating to definitions of complex trial designs was successfully held on 5 February 2018 in partnership with regulatory bodies (Health Research Authority, Medicines and Healthcare products Regulatory Agency (MHRA)) and other stakeholders including the research community (ECMC, Cancer Research UK, and Clinical Trials Units), devolved administrations and industry associations (The Association of the British Pharmaceutical Industry and UK BioIndustry Association).
The HRA is currently inviting MPEs and CREs to register to become HRA Radiation Assurance Reviewers
2017 has been a busy year for the ECMC network.
The new 5 year review officially started in April. With the renewed agreement of the 5 co-funders (CRUK; NIHR: CSO; HCRW; HSC), and on the back of a successful international peer review, we welcomed Liverpool back in the adult network, and saw an expansion from 9 to 11 locations in the paediatric network, with Southampton and Cambridge joining as new centres.
Following interest expressed by centres across the ECMC network, a newly established ECMC Haematology Network Group, led by Cardiff ECMC, met for the first time on the 25th October in the Hammersmith Hospital, with seven centres represented.
A key objective of the group is to strengthen the representation of Haematology within the ECMC Network, with the goal of enhancing the clinical and scientific contributions by this discipline.
Dr David Pinato has been awarded with a Cancer Research UK Postdoctoral Bursary for his project - Phenotypic characterisation of the anti-tumour immune response following loco-regional therapy of hepatocellular carcinoma.
It has been yet another busy year for the Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) so we would like to extend a huge thank you to all our colleagues for their continued hard work and support, as well as to all the patients and their families who signed up to this new, innovative trial.
A trial to test an experimental drug in patients with head and neck cancer launches in the UK today (Friday), through the Combinations Alliance – a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network.
The winners of the 2017 Greater Manchester Clinical Research Awards were revealed during an evening of celebration on Thursday 9 November. Staff from across the region’s Trusts and GP practices gathered in Manchester city centre for the fifth-annual ceremony to toast excellence in health research delivery. Individuals and teams were rewarded for their efforts across 10 categories, while special awards were also presented to an extra four outstanding recipients.
The Molto study has opened at the Christie Hospital, Manchester. The trial is recruiting women with a germline BRCA1/2 mutation and recurrent, platinum-sensitive, high-grade serous or endometrioid ovarian cancer.